Alambic Investment Management L.P. lowered its position in shares of Amedisys Inc (NASDAQ:AMED) by 4.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,650 shares of the health services provider’s stock after selling 1,300 shares during the period. Alambic Investment Management L.P.’s holdings in Amedisys were worth $2,363,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in Amedisys during the first quarter valued at approximately $123,000. Itau Unibanco Holding S.A. bought a new stake in Amedisys during the second quarter valued at approximately $149,000. Mount Yale Investment Advisors LLC bought a new stake in Amedisys during the first quarter valued at approximately $151,000. Quantitative Systematic Strategies LLC bought a new stake in Amedisys during the second quarter valued at approximately $217,000. Finally, IFG Advisory LLC bought a new stake in Amedisys during the second quarter valued at approximately $221,000. 93.35% of the stock is owned by institutional investors.
Shares of AMED opened at $123.51 on Friday. The company has a market capitalization of $3.98 billion, a PE ratio of 55.89, a price-to-earnings-growth ratio of 1.97 and a beta of 0.99. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21. Amedisys Inc has a fifty-two week low of $45.60 and a fifty-two week high of $126.30.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, July 31st. The health services provider reported $1.00 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.22. The firm had revenue of $411.60 million during the quarter, compared to analyst estimates of $403.62 million. Amedisys had a net margin of 4.46% and a return on equity of 20.11%. During the same period in the previous year, the business posted $0.62 EPS. equities research analysts expect that Amedisys Inc will post 3.41 earnings per share for the current year.
In related news, Director Jake L. Netterville sold 4,096 shares of Amedisys stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $80.44, for a total value of $329,482.24. Following the transaction, the director now directly owns 77,660 shares of the company’s stock, valued at $6,246,970.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction on Wednesday, July 25th. The stock was sold at an average price of $94.18, for a total transaction of $37,483.64. Following the completion of the transaction, the insider now directly owns 12,216 shares in the company, valued at $1,150,502.88. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.
AMED has been the subject of several research analyst reports. Royal Bank of Canada lifted their target price on shares of Amedisys to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 3rd. Robert W. Baird lifted their target price on shares of Amedisys from $67.00 to $72.00 and gave the company a “neutral” rating in a research report on Tuesday, June 5th. Stephens reiterated a “hold” rating and set a $78.00 target price on shares of Amedisys in a research report on Tuesday, June 5th. Bank of America upgraded shares of Amedisys from a “neutral” rating to a “buy” rating and lifted their target price for the company from $88.00 to $97.00 in a research report on Tuesday, July 3rd. Finally, ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 30th. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Amedisys currently has an average rating of “Buy” and a consensus target price of $77.09.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Article: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.